Trimel Pharmaceuticals Corporation (Trimel) is a development-stage specialty pharmaceutical company. It is engaged in developing medications for male hypogonadism, female sexual dysfunction, and various respiratory disorders. The Company holds the development and marketing rights to a bioadhesive intranasal gel drug delivery technology platform and owns a novel dry power drug delivery technology platform and is pursuing the development and application of these technologies to products that are in Phase II and Phase III clinical testing. These drug delivery platforms are a bioadhesive intranasal gel and a unit dose dry powder inhaler/nasal dispersion system. Trimel�s targeted indications include male hypogonadism (low testosterone or Low-T), female sexual dysfunction (anorgasmia), and respiratory disorders (asthma). In July 2014, the Company acquired from Shire plc, the Canadian rights for Estrace (17-beta estradiol).